Christopher Gibson, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the reliability of next-generation sequencing (NGS) at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX. Dr Gibson explains that results from NGS have been reliable as the mutations seen are those that are present in Acute myeloid leukemia (AML). Dr Gibson also questions the relevance on the results and how this is entirely dependent on expert interpretation.
How reliable is NGS in diagnosing AML?
